Updated: Early sales of Lilly’s obesity pill appear to trail Novo’s

April 30, 2026 07:19 AM EDTUpdated 07:38 AM Pharma Lack of specifics on obe­si­ty pill sales hov­er over Lil­ly’s first quar­ter Elizabeth Cairns Senior biopharma journalist In­vestors hop­ing for more ac­cu­rate sales fig­ures for Foun­dayo, Eli Lil­ly’s new­ly launched obe­si­ty pill, were dis­ap­point­ed Thurs­day when the com­pa­ny did not re­veal them … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER